Infections in Hematopoietic Stem Cell Transplant Recipients

  • Georg Maschmeyer
  • Per Ljungman
Part of the Current Clinical Oncology book series (CCO)


The risk of infection among allogeneic hematopoietic­ stem cell transplant (aHSCT) recipients is determined by patient age, underlying disease, the complications that occurred during preceding treatment regimens, the selected transplantation modality, and the severity of graft-versus-host disease. Immunological reconstitution after hematopoietic recovery has an impact on the type of posttransplant infectious complications, and infection-related mortality is significantly higher postengraftment than during the short posttransplant neutropenia. As different pathogenetic and epidemiological backgrounds of infections occur following aHSCT, three consecutive time periods posttransplant are separately described: the early posttransplant period (preengraftment, comprising 3 weeks), the intermediate posttransplant period (3 weeks to 3 months), and the late posttransplant period (later than day  +  90).


Allogeneic Hematopoietic stem cell transplant Early infection CMV Late infections Graft-versus-host disease 


  1. 1.
    Walter E, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am. 1995;9:823–47.PubMedGoogle Scholar
  2. 2.
    Krüger WH, Bohlius J, Cornely OA, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol. 2005;16:1381–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.PubMedCrossRefGoogle Scholar
  4. 4.
    Welniak LA, Blazar BR, Murphy WJ. Immunobiology ofallogeneic­ hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Aschan J. Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol. 2007;20:295–310.PubMedCrossRefGoogle Scholar
  6. 6.
    Bachanova V, Brunstein CG, Burns LJ, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant. 2009;43:237–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Baron F, Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol. 2007;14:145–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8:512–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis. 2004;6:171–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Blijlevens NM, Donnelly JP, de Pauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant. 2005;35:707–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:143–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Krüger W, Rüssmann B, Kröger N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases. Bone Marrow Transplant. 1999;23:589–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuen KY, Woo PCY, Hui CH, et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant. 1998;21:1137–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation - Epidemiology and interventional therapy strategies. Ann Hematol. 2003;82 Suppl 2:S175–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol. 1999;17:796–805.PubMedGoogle Scholar
  18. 18.
    Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139:519–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis. 1984;149:750–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 2000;181:2055–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2001;28:479–84.PubMedCrossRefGoogle Scholar
  24. 24.
    McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant. 2004;33:519–29.PubMedCrossRefGoogle Scholar
  25. 25.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Machado CM. Influenza infections after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;41:273–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31:295–300.PubMedCrossRefGoogle Scholar
  29. 29.
    Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol. 2006;77:255–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Hsiao LT, Chiou TJ, Liu JH, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:84–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Hamadani M, Hofmeister CC, Jansak B, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008;14:783–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768–76.PubMedCrossRefGoogle Scholar
  33. 33.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMedCrossRefGoogle Scholar
  34. 34.
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42:227–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:471–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in Leukemia. Bone Marrow Transplant. 2009;43:757–70.PubMedCrossRefGoogle Scholar
  38. 38.
    Micallef IN, Chanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant. 1998;22:981–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant. 2003;32:97–102.PubMedCrossRefGoogle Scholar
  40. 40.
    Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059–67.PubMedGoogle Scholar
  41. 41.
    Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.PubMedCrossRefGoogle Scholar
  42. 42.
    Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein–Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol. 2002;40:351–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Greenfield HM, Gharib MI, Turner AJ, et al. The impact of monitoring Epstein–Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr Blood Cancer. 2006;47:200–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39:235–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–92.PubMedCrossRefGoogle Scholar
  49. 49.
    Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11:393–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. 1985;312:529–33.PubMedCrossRefGoogle Scholar
  51. 51.
    Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775–81.PubMedCrossRefGoogle Scholar
  52. 52.
    Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–27.PubMedCrossRefGoogle Scholar
  53. 53.
    Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102:1114–20.PubMedCrossRefGoogle Scholar
  54. 54.
    Van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36:39–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma. 2007;48:244–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica. 2007;92:1254–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Symeonidis N, Jakubowski A, Pierre-Louis S, Jaffe D, Pamer E, Sepkowitz K, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis. 2007;9:108–13.PubMedCrossRefGoogle Scholar
  58. 58.
    Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31:481–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006;81:1398–404.PubMedCrossRefGoogle Scholar
  60. 60.
    Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant. 2007;13:74–81.PubMedCrossRefGoogle Scholar
  61. 61.
    Drobyski WR, Dunne WM, Burd EM, et al. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. J Infect Dis. 1993;167:735–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Carrigan DR, Knox KK. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood. 1994;84:3307–10.PubMedGoogle Scholar
  63. 63.
    Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis. 1999;28:562–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Zerr DM, Gooley TA, Yeung L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;33:763–71.PubMedCrossRefGoogle Scholar
  65. 65.
    Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:309–17.PubMedCrossRefGoogle Scholar
  66. 66.
    Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98:1971–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106:1130–2.PubMedCrossRefGoogle Scholar
  69. 69.
    Chen CS, Boeckh M, Seidel K, et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:515–22.PubMedCrossRefGoogle Scholar
  70. 70.
    De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36:879–83.PubMedCrossRefGoogle Scholar
  71. 71.
    Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38:1229–36.PubMedCrossRefGoogle Scholar
  72. 72.
    Erdstein AA, Daas P, Bradstock KF, Robinson T, Hertzberg MS. Tuberculous in allogeneic stem cell transplant recipients: still a problem in the 21st century. Transpl Infect Dis. 2004;6:142–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–14.PubMedCrossRefGoogle Scholar
  74. 74.
    Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172–81.PubMedCrossRefGoogle Scholar
  76. 76.
    Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25:657–64.PubMedCrossRefGoogle Scholar
  77. 77.
    Martino R, Rovira M, Carreras E, et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica. 2001;86:1075–86.PubMedGoogle Scholar
  78. 78.
    Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus ­disease after allogeneic hematopoietic cell transplantation – a ­randomized double-blind placebo-controlled study. Blood. 2006;107:1800–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Erard V, Guthrie KA, Varley C, et al. One-year acyclovir ­prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood. 2007;110:3071–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193:1619–25.PubMedCrossRefGoogle Scholar
  82. 82.
    Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88:1222–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von BergmannPotsdamGermany

Personalised recommendations